Deucravacitinib trials for Psoriasis

All Deucravacitinib trials · All Psoriasis trials

Phase breakdown

Recruiting trials studying Deucravacitinib for Psoriasis

• A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
  NCT05744466 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)
  NCT06701513 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 48 locations
• A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)
  NCT06382987 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Study to Assess Deucravacitinib Safety in Pregnancy
  NCT07017699 · Phase: Not specified · Ages: No age limits stated · Sex: Female · 1 location
• A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis
  NCT04772079 · Phase: Phase 3 · Ages: 4 Years to 18 Years · Sex: All (male and female) · 65 locations
• A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
  NCT06979453 · Phase: Phase 3 · Ages: 12 Years to 17 Years · Sex: All (male and female) · 132 locations
• Correction of Psoriatic T Cell Signatures by Deucravacitinib
  NCT05858645 · Phase: Phase 4 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy
  NCT07256015 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease
  NCT07280702 · Phase: Phase 4 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
  NCT07116967 · Phase: Phase 3 · Ages: 40 Years and older · Sex: All (male and female) · 402 locations
• Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea
  NCT06258668 · Phase: Not specified · Ages: 19 Years and older · Sex: All (male and female) · 2 locations

Common questions

How many trials study Deucravacitinib for Psoriasis?

11 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.